Innovent's Mazdutide Demonstrates Notable Weight Loss and Metabolic Advantages in Chinese Teenagers

Clinical Trial Success: Innovent Biologics' Phase 1b trial of mazdutide injection in Chinese adolescents with obesity met its primary endpoint, showing significant BMI and weight reductions compared to placebo.

Study Details: The trial involved 36 adolescents aged 12-18 who had not achieved sufficient weight loss through diet and exercise, with the mazdutide groups achieving BMI reductions of 8.78% and 10.99%.

Safety Profile: Mazdutide demonstrated a favorable safety and tolerability profile, with no serious adverse events reported and only mild to moderate gastrointestinal side effects observed.

Future Plans: Innovent plans to initiate a Phase 3 trial to further evaluate mazdutide, addressing the urgent need for effective obesity treatments in adolescents, as no weight-loss medications are currently approved for this age group in China.